Use of Obinutuzumab for B-cell Malignancies

Main Article Content

Mita Manna Carolyn Jane Owen

Abstract

We analysed data for the use of obinutuzumab in the treatment of CD20-positive lymphoproliferative disorders including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphomas (NHL). Marked progress in the outcomes of B-cell NHL came with the development of targeted therapy against CD20 with the monoclonal antibody rituximab. Despite the benefit seen with rituximab, many patients relapse or become refractory after rituximab-containing therapies. This led to the development of more effective anti-CD20 monoclonal antibodies such as obinutuzumab. Several Phase III studies have been conducted comparing rituximab to obinutuzumab in patients with B-cell NHL. Obinutuzumab is a glycoengineered Type II anti-CD20 monoclonal antibody. An overview of the recently presented and/or published Phase III studies investigating obinutuzumab in the treatment of NHL and CLL are presented. The CLL11 Phase III study was the first study demonstrating the superiority of obinutuzumab over rituximab. Recently, several other Phase III studies have demonstrated improved outcomes for CLL and NHL with the use of obinutuzumab. Further evaluation, longer follow-up, and future studies investigating combination therapy with novel agents are warranted to demonstrate if obinutuzumab should replace rituximab as the standard of care.

Article Details

How to Cite
MANNA, Mita; OWEN, Carolyn Jane. Use of Obinutuzumab for B-cell Malignancies. Medical Research Archives, [S.l.], v. 5, n. 4, apr. 2017. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/1196>. Date accessed: 13 apr. 2024.
Keywords
antibody, CD20, chronic lymphocytic leukemia, non-Hodgkin lymphoma, obinutuzumab
Section
Review Articles

References

1. Glenni MJ, French RR, Cragg MS et al. Mechanisms of kiling by anti-CD20 monoclonal ntibodies. Mol Immunol. 2007;44(16):3823–37.

2. Coiffier B, Thieblemont C, Van Den Neste E et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116(12):2040–5.

3. Hallek M, Fischer K, Fingerle-Rowson G et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.

4. Marcus R, Imrie K, Belch A et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105(4):1417–23.

5. Lemery SJ, Zhang J, Rothmann MD et al. US Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab. Clin Cancer Res. 2010;16(17):4331–8.

6. Goede V, Fischer K, Busch R et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10.

7. Owen CJ, Stewart DA. Obinutuzumab for B-cell malignancies. Expert Opin Biol Ther. 2014;2598(12):1–9.

8. Owen C, Stewart D a. Obinutuzumab for the treatment of lymphoproliferative disorders. Expert Opin Biol Ther. 2012;12(3):343–51.

9. Sehn LH, Assouline SE, Stewart D a, Mangel J, Gascoyne RD, Frances-lasserre S, et al. maintenance in patients with relapsed CD20-positive B-cell malignancies A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies. Blood. 2013;119(22):5118–25.

10. Salles G, Morschhauser F, Lamy T, Milpied N, Thieblemont C, Tilly H, et al. lymphoma patients Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab ( GA101 ) in B-cell lymphoma patients. 2013;119(22):5126–32.

11. Sehn LH, Goy A, Offner FC et al. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015;33(30):3467–74.

12. Goede V, Fischer K, Engelke A et al. Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study. Leukemia. 2015;29:1602–4.

13. Bosch, F., Illmer, T., Turgut, M., Cortelezzi, A., Lasserre, S. F., Truppel-Hartmann, A., Leblond, V., Foà, R., & Stilgenbauer S. Preliminary Safety Results from the Phase IIIb GREEN Study of Obinutuzumab (GA101) Alone or in Combination with Chemotherapy for Previously Untreated or Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood. 2014;124(21):3345.

14. Stilgenbauer, S., Ilhan, O., Woszczyk, D., Renner, C., Mikuskova, E., Böttcher, S., Tausch, E., Moore, T., Tyson, N., Adamis, H., Leblonde, V., Bosch, F., & Foà R. Safety and Efficacy of Obinutuzumab Plus Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the Green Study. Blood. 2016;126(23):493.

15. Marcus RE, Davies AJ, Ando K et al. Obinutuzumab-Based Induction and Maintenance Prolongs Progression-Free Survival (PFS) in Patients with Previously Untreated Follicular Lymphoma: Primary Results of the Randomized Phase 3 GALLIUM Study. ASH Annu Meet Abstr. 2016.

16. Pott C, Hoster E, Kehden B et al. Minimal Residual Disease in Patients with Follicular Lymphoma Treated with Obinutuzumab or Rituximab As First-Line Induction Immunochemotherapy and Maintenance in the Phase 3 GALLIUM Study. ASH Annu Meet Abstr. 2016.

17. Sehn LH, Chua N, Mayer J et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol [Internet]. Available from: http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(16)30097-3.pdf.

18. Cheson BD, Trněný M, Bouabdallah K et al. Obinutuzumab plus Bendamustine Followed by Obinutuzumab Maintenance Prolongs Overall Survival Compared with Bendamustine Alone in Patients with Rituximab-Refractory Indolent Non-Hodgkin Lymphoma: Updated Results of the GADOLIN Study. ASH Annu Meet Abstr. 2016.

19. Sehn LH, Donaldson J, Chhanabhai M et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–33.

20. Vitolo U, Trněný M, Belada D et al. Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma: Final Results from an Open-Label, Randomized Phase 3 Study (GOYA). ASH Annu Meet Abstr. 2016.

21. O’Brien SM, Kantarjian H T, DA et al. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol. 2001;19:2165–70.

22. O’Brien S, Wierda WG, Federl S et al. FCR-3 as frontline therapy for patients with chronic lymphocytic leukemia. Blood (ASH Annu Meet Abstr. 2005;106:2117.

23. Davies A, Merli F, Mihaljevic B, Siritanaratkul N, Solal-Céligny P, Barrett M, et al. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study. Lancet Oncol. 2017;15(3):343–52.